Provided by Tiger Trade Technology Pte. Ltd.

Lexaria Bioscience Corp

0.6497
+0.02724.37%
Post-market: 0.6233-0.0264-4.06%19:31 EST
Volume:64.57K
Turnover:41.25K
Market Cap:16.17M
PE:-1.15
High:0.6900
Open:0.6161
Low:0.6000
Close:0.6225
52wk High:1.90
52wk Low:0.4600
Shares:24.89M
Float Shares:23.45M
Volume Ratio:0.41
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5629
EPS(LYR):-0.6613
ROE:-155.23%
ROA:-82.96%
PB:3.29
PE(LYR):-0.98

Loading ...

Lexaria Bioscience Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance

Reuters
·
Feb 07

Lexaria Bioscience Reports Positive Results for Oral Liraglutide in Human Pilot Study

Reuters
·
Feb 05

Lexaria Bioscience Corp. Held Annual Shareholder Meeting

Reuters
·
Jan 29

Lexaria Bioscience Corp. Granted Six New Patents, Bringing Total to 60 Worldwide

Reuters
·
Jan 22

Lexaria Bioscience Q1 net loss narrows to USD 1.6 million

Reuters
·
Jan 14

Lexaria CEO says ‘closer to a commercial breakthrough than ever before’

TIPRANKS
·
Jan 12

Lexaria Bioscience Corp. Pursues Pharmaceutical Partnerships and Reports Progress on Technology Development

Reuters
·
Jan 12

Lexaria Bioscience Reports Positive Results from Phase 1b GLP-1-H24-4 Clinical Study

Reuters
·
Dec 30, 2025

Lexaria Bioscience Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 26, 2025

Lexaria Bioscience Corp. : H.c. Wainwright Cuts Target Price to $1.5 From $4

THOMSON REUTERS
·
Dec 26, 2025

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

Benzinga_recent_news
·
Dec 24, 2025

Lexaria Bioscience Achieves Primary Endpoint in GLP-1 Clinical Study with DehydraTECH Outperforming Rybelsus

Reuters
·
Dec 23, 2025

Lexaria Bioscience Issues Warrants to Purchase 2.66 Million Shares

Reuters
·
Dec 17, 2025

Top Midday Decliners

MT Newswires Live
·
Dec 16, 2025

Lexaria Bioscience FY IP Licensing Revenue Rises to USD 0.7 Million, Up 52%

Reuters
·
Nov 28, 2025

Lexaria Bioscience Extends Material Transfer Agreement with Pharmaceutical Company

Reuters
·
Nov 12, 2025

Lexaria Bioscience Corp. Awarded Four New Patents Covering Diabetes, Epilepsy, Antiviral Treatments, and More

Reuters
·
Oct 09, 2025

BRIEF-Lexaria Bioscience enters securities purchase agreement with investors - SEC filing

Reuters
·
Sep 30, 2025

Lexaria Bioscience Corp - Enters Securities Purchase Agreement With Investors - SEC Filing

THOMSON REUTERS
·
Sep 30, 2025

Nasdaq Gains 100 Points; US Consumer Sentiment Falls

Benzinga
·
Sep 27, 2025